Deficiency of parkin causes neurodegeneration and accumulation of pathological α-synuclein in monkey models.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
    • Publication Information:
      Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
      Original Publication: New Haven [etc.] American Society for Clinical Investigation.
    • Subject Terms:
      Ubiquitin-Protein Ligases*/genetics ; Ubiquitin-Protein Ligases*/metabolism ; Ubiquitin-Protein Ligases*/deficiency ; alpha-Synuclein*/metabolism ; alpha-Synuclein*/genetics ; Disease Models, Animal* ; Parkinson Disease*/genetics ; Parkinson Disease*/metabolism ; Parkinson Disease*/pathology; Animals ; Phosphorylation ; Protein Kinases/genetics ; Protein Kinases/metabolism ; Humans ; Substantia Nigra/metabolism ; Substantia Nigra/pathology ; Macaca fascicularis ; Mice ; Male
    • Abstract:
      Parkinson's disease (PD) is characterized by age-dependent neurodegeneration and the accumulation of toxic phosphorylated α-synuclein (pS129-α-syn). The mechanisms underlying these crucial pathological changes remain unclear. Mutations in parkin RBR E3 ubiquitin protein ligase (PARK2), the gene encoding parkin that is phosphorylated by PTEN-induced putative kinase 1 (PINK1) to participate in mitophagy, cause early onset PD. However, current parkin-KO mouse and pig models do not exhibit neurodegeneration. In the current study, we utilized CRISPR/Cas9 technology to establish parkin-deficient monkey models at different ages. We found that parkin deficiency leads to substantia nigra neurodegeneration in adult monkey brains and that parkin phosphorylation decreases with aging, primarily due to increased insolubility of parkin. Phosphorylated parkin is important for neuroprotection and the reduction of pS129-α-syn. Consistently, overexpression of WT parkin, but not a mutant form that cannot be phosphorylated by PINK1, reduced the accumulation of pS129-α-syn. These findings identify parkin phosphorylation as a key factor in PD pathogenesis and suggest it as a promising target for therapeutic interventions.
    • References:
      J Cell Biol. 2014 Apr 28;205(2):143-53. (PMID: 24751536)
      Exp Neurol. 2013 Feb;240:190-204. (PMID: 23201181)
      Nature. 1997 Aug 28;388(6645):839-40. (PMID: 9278044)
      J Neurochem. 2009 Aug;110(3):1005-13. (PMID: 19493164)
      Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11696-701. (PMID: 26324925)
      Acta Neuropathol. 2021 May;141(5):725-754. (PMID: 33694021)
      Neural Regen Res. 2025 Apr 1;20(4):1124-1134. (PMID: 38989951)
      Mov Disord. 2002 Nov;17(6):1374-80. (PMID: 12465088)
      Neurosci Bull. 2019 Apr;35(2):270-276. (PMID: 30411305)
      Science. 2013 Jun 21;340(6139):1451-5. (PMID: 23661642)
      Sci Rep. 2016 Feb 09;6:20620. (PMID: 26857844)
      Nat Cell Biol. 2002 Feb;4(2):160-4. (PMID: 11813001)
      Acta Neuropathol. 2012 Jun;123(6):901-3. (PMID: 22555654)
      Biochem Soc Trans. 2010 Feb;38(Pt 1):144-9. (PMID: 20074049)
      Neurology. 2004 Aug 24;63(4):678-82. (PMID: 15326242)
      Cell Death Dis. 2023 Mar 1;14(3):176. (PMID: 36859484)
      Brain. 2020 Jul 1;143(7):2220-2234. (PMID: 32613234)
      Clin Chim Acta. 2004 Jan;339(1-2):1-9. (PMID: 14687888)
      Mov Disord. 2017 Nov;32(11):1504-1523. (PMID: 29124790)
      Cell Metab. 2018 Feb 6;27(2):439-449.e5. (PMID: 29337137)
      Cell Discov. 2023 Mar 7;9(1):27. (PMID: 36878905)
      Nature. 2014 Jun 5;510(7503):162-6. (PMID: 24784582)
      Mol Neurodegener. 2020 Mar 13;15(1):20. (PMID: 32169097)
      Open Biol. 2018 Nov 7;8(11):. (PMID: 30404819)
      PLoS One. 2009 Jun 03;4(6):e5777. (PMID: 19492057)
      Nat Commun. 2023 Nov 18;14(1):7497. (PMID: 37980356)
      Acta Neuropathol. 2021 Sep;142(3):423-448. (PMID: 34115198)
      PLoS One. 2011 Jan 13;6(1):e16038. (PMID: 21249202)
      Neurology. 1994 Mar;44(3 Pt 1):437-41. (PMID: 8145912)
      BMC Neurosci. 2005 Dec 24;6:71. (PMID: 16375772)
      J Neurosci. 2005 Aug 31;25(35):7968-78. (PMID: 16135753)
      Autophagy. 2008 Jan;4(1):85-7. (PMID: 17957134)
      Ann Neurol. 2005 Sep;58(3):411-22. (PMID: 16130111)
      Protein Cell. 2022 Jan;13(1):26-46. (PMID: 34800266)
      Lancet Neurol. 2015 Feb;14(2):136. (PMID: 25772887)
      Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73. (PMID: 9600990)
      Neuron. 2015 Jan 21;85(2):257-73. (PMID: 25611507)
      J Cell Biol. 2017 Oct 2;216(10):3231-3247. (PMID: 28893839)
      PLoS Genet. 2014 May 08;10(5):e1004302. (PMID: 24810576)
      Clinics (Sao Paulo). 2006 Oct;61(5):417-24. (PMID: 17072439)
      J Biol Chem. 2010 Dec 24;285(52):40732-44. (PMID: 20959456)
      Front Cell Neurosci. 2019 Jul 05;13:297. (PMID: 31333417)
      Cells. 2021 Jan 31;10(2):. (PMID: 33572534)
      Cell Res. 2019 Apr;29(4):334-336. (PMID: 30770867)
      Zool Res. 2024 Mar 18;45(2):242-252. (PMID: 38287905)
      Mov Disord. 2013 Mar;28(3):388-91. (PMID: 23401296)
      Cell Tissue Res. 2004 Oct;318(1):175-84. (PMID: 15503153)
      Sci Rep. 2012;2:1002. (PMID: 23256036)
      Neurology. 1998 Sep;51(3):890-2. (PMID: 9748052)
      Mov Disord. 2014 Apr;29(4):566-8. (PMID: 24375549)
      Open Biol. 2012 May;2(5):120080. (PMID: 22724072)
      Oxid Med Cell Longev. 2021 Dec 13;2021:2060986. (PMID: 34938381)
      Nat Struct Mol Biol. 2018 Jul;25(7):623-630. (PMID: 29967542)
      Neurol Genet. 2016 May 03;2(3):e73. (PMID: 27182553)
      EMBO J. 2013 Jul 31;32(15):2099-112. (PMID: 23727886)
      Brain Res. 2015 Dec 2;1628(Pt B):247-253. (PMID: 26080075)
      Sci Rep. 2017 Feb 03;7:42081. (PMID: 28155910)
      Biochem J. 2014 May 15;460(1):127-39. (PMID: 24660806)
      Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11441-6. (PMID: 17563363)
      J Cell Biol. 2018 May 7;217(5):1613-1622. (PMID: 29500189)
      Mov Disord. 2021 Jul;36(7):1634-1643. (PMID: 33570211)
      Ann Neurol. 2001 Sep;50(3):293-300. (PMID: 11558785)
      Nature. 2018 Jul;559(7714):410-414. (PMID: 29995846)
      Neuron. 2003 Sep 11;39(6):889-909. (PMID: 12971891)
      Mol Cell. 2014 Nov 6;56(3):360-375. (PMID: 25284222)
      Cell Mol Life Sci. 2015 Mar;72(6):1175-84. (PMID: 25274063)
      J Biol Chem. 2003 Oct 31;278(44):43628-35. (PMID: 12930822)
      Mol Neurodegener. 2019 May 2;14(1):17. (PMID: 31046796)
      J Neurosci. 2015 May 27;35(21):8345-58. (PMID: 26019347)
      Nat Rev Dis Primers. 2021 Jul 1;7(1):47. (PMID: 34210995)
      EMBO Rep. 2015 Sep;16(9):1114-30. (PMID: 26162776)
      Acta Neuropathol. 2019 Jun;137(6):919-937. (PMID: 30810811)
      J Biol Chem. 2006 Oct 6;281(40):29739-52. (PMID: 16847063)
    • Contributed Indexing:
      Keywords: Aging; Neuroscience; Parkinson disease
    • Accession Number:
      EC 2.3.2.27 (Ubiquitin-Protein Ligases)
      EC 2.3.2.27 (parkin protein)
      0 (alpha-Synuclein)
      EC 2.7.11.1 (PTEN-induced putative kinase)
      EC 2.7.- (Protein Kinases)
    • Publication Date:
      Date Created: 20241015 Date Completed: 20241015 Latest Revision: 20241018
    • Publication Date:
      20241018
    • Accession Number:
      PMC11473153
    • Accession Number:
      10.1172/JCI179633
    • Accession Number:
      39403921